Dr. Bruce Quinn is an expert on health reform, innovation, and Medicare policy. A pathologist by training, he has worked on a wide range of federal health policy issues ranging from biopharma to genomics. After a career in academic medicine, he was a physician executive with Accenture, serving clients in both the biopharma and payer industries. After a stint as an executive with Medicare, he has been a full-time life sciences strategy consultant, serving clients of two major law firms, Foley Hoag LLP and Faegre Baker Daniels LLP. Since 2017, Dr. Quinn manages his own Medtech and biopharma consulting practice based in Los Angeles and San Francisco. His blog, Discoveries in Health Policy, current logs over 100,000 hits per year. Dr. Quinn has helped leading companies in both medical device and genomics negotiate with CMS agency on coding, coverage, and policy issues.
Reimbursement of diagnostic tests are a core component of Precision Medicine. Convincing payers of the medical necessity of a new diagnostic test can be challenging. Timely access for patients with the most compelling unmet needs requires the reimbursement environment transition to a transparent value-based model using fit-for-purpose levels of evidence.